Stockreport

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

IO Biotech, Inc.  (IOBT) 
PDF Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients [Read more]